308 reports of this reaction
5.5% of all CARVEDILOL PHOSPHATE reports
#1 most reported adverse reaction
DIZZINESS is the #1 most commonly reported adverse reaction for CARVEDILOL PHOSPHATE, manufactured by Waylis Therapeutics LLC. There are 308 FDA adverse event reports linking CARVEDILOL PHOSPHATE to DIZZINESS. This represents approximately 5.5% of all 5,587 adverse event reports for this drug.
Patients taking CARVEDILOL PHOSPHATE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among CARVEDILOL PHOSPHATE users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for CARVEDILOL PHOSPHATE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 308 FDA reports for CARVEDILOL PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 5.5% of all adverse event reports for CARVEDILOL PHOSPHATE, making it one of the most commonly reported side effect.
If you experience dizziness while taking CARVEDILOL PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.